SCHEMBL18166709

SCHEMBL18166709

Cn1c(=O)c2c(ncn2CC(=O)Nc2nc(-c3ncccn3)cs2)n(C)c1=O

nearest known ligand 0.73

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.73
▸ LMNA P02545 1/20 0.73
▸ MAPT P10636 2/20 0.70
▸ RXFP1 Q9HBX9 6/20 0.64
▸ CYP1A2 P05177 1/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ PORCN Q9H237 1/20 0.55
▸ THRB P10828 1/20 0.55
▸ TP53 P04637 2/20 0.55
▸ ALOX15 P16050 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18166696 0.90 SMN1; SMN2 (0.75) SMN1; SMN2LMNAMAPTRXFP1CYP1A2
SCHEMBL18166618 0.89 MAPT (0.79) SMN1; SMN2LMNAMAPTRXFP1CYP1A2
SCHEMBL9972920 0.88 MAPT (0.77) SMN1; SMN2LMNAMAPTRXFP1CYP1A2
SCHEMBL18166675 0.86 MAPT (0.73) SMN1; SMN2LMNAMAPTRXFP1CYP1A2
SCHEMBL18166649 0.85 SMN1; SMN2 (0.82) SMN1; SMN2LMNAMAPTRXFP1CYP1A2
SCHEMBL18166643 0.85 RXFP1 (0.72) SMN1; SMN2LMNAMAPTRXFP1CYP1A2
SCHEMBL16440384 0.85 MAPT (0.73) SMN1; SMN2LMNAMAPTRXFP1CYP1A2
SCHEMBL27793543 0.85 MAPT (0.79) SMN1; SMN2LMNAMAPTRXFP1CYP1A2
SCHEMBL10114670 0.85 MAPT (0.82) SMN1; SMN2LMNAMAPTRXFP1CYP1A2
SCHEMBL18166722 0.84 SMN1; SMN2 (0.81) SMN1; SMN2LMNAMAPTRXFP1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3663295-A1 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL ELI LILLY AND CO. (US) 2020-06-10 — — EP disclosed
EP-3184527-A1 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL Hydra Biosciences, Inc. (US) 2017-06-28 — — EP disclosed
EP-2170309-B1 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL HYDRA BIOSCIENCES INC (US) 2016-10-26 — — EP disclosed
Send feedback